Boston Scientific Corporation (BSX)

Boston Scientific's stock reached an all-time high of $108.14 on September 8, 2025. In October 2025, the company announced strong third-quarter results, with net sales of $5.065 billion and adjusted EPS of $0.75. In February 2026, the stock declined after quarterly sales disappointed investors, and the 2026 adjusted EPS guidance fell below estimates, leading to a 17.59% drop on February 4, 2026. The stock also dropped following the announcement of an agreement to acquire Penumbra, due to concerns about earnings dilution and financing the deal with new debt.

There is no explicit information indicating significant demand seasonality for Boston Scientific's products and services. The company has reported strong and accelerated demand, with consistent year-on-year revenue growth. Analysts anticipate continued growth, suggesting a steady rather than seasonal demand pattern. The fundamental demand for the company's products is expected to continue growing due to factors like an aging population and increasing chronic diseases.

Boston Scientific Corporation is a global medical technology leader focused on interventional medical specialties. The company provides a range of high-performance medical devices across various therapeutic areas. Its major products include cardiovascular devices like the WATCHMAN and EMBLEM S-ICD, and electrophysiology products like the FARAPULSE PFA system. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation, with recent expansions through acquisitions like Axonics, Inc. and Nalu Medical. The company emphasizes catheter-based, implantable, and endoscopic technologies.

Boston Scientific operates globally, serving approximately 140 countries. Its global corporate headquarters is in Marlborough, Massachusetts, with regional headquarters in Singapore and Paris. The company has major technology centers in Minnesota, California, Ireland, and Costa Rica, and 13 manufacturing facilities worldwide. In 2024, Boston Scientific demonstrated strong double-digit operational growth in all regions, with sales increasing by 21.2% in the United States, 13.8% in Europe, Middle East and Africa (EMEA), 15.7% in Asia Pacific (APAC), and 14.1% in Latin America and Canada (LACA) compared to 2023. Net sales in Emerging Markets countries grew 19.6% operationally in 2024.

Boston Scientific maintains a strong reputation in the medical technology industry due to its focus on innovation and patient health. Consistent financial performance and exceeding financial goals in 2025 contribute positively to its standing. MarketBeat ranked Boston Scientific higher than 88% of companies in the medical sector. The company has a consensus rating of "Moderate Buy" from analysts. Recent stock declines reflect investor reactions to financial forecasts and market competition rather than a fundamental erosion of the company's brand.

Institutional investors hold approximately 89.07% of Boston Scientific's stock, with major holders including BlackRock, Inc., Vanguard Group Inc, Fmr Llc, and State Street Corp. Insiders hold around 0.50% of the stock, and have sold more stock than they have bought in the past three months.